Why WADA Bans Peptides: The Full Rationale

Peptide Doping & Anti-Doping

23 substance classes

The WADA Prohibited List covers 23 substance classes, but only 5 have strong evidence of performance enhancement. Peptide hormones are banned anyway.

Heuberger & Cohen, Sports Medicine, 2019

Heuberger & Cohen, Sports Medicine, 2019

View as image

The World Anti-Doping Agency bans dozens of peptides, from growth hormone releasing peptides like GHRP-6 to regenerative compounds like thymosin beta-4. But the rationale is more nuanced than "peptides make athletes faster." WADA uses a three-criteria framework, and a substance only needs to meet two of the three to be prohibited. Some banned peptides have strong evidence of performance enhancement. Others are banned primarily because they pose health risks or because no approved therapeutic use exists. Understanding the distinction matters for athletes, coaches, and anyone following the science of peptides.

This article breaks down the S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics), explains WADA's decision framework, examines the evidence (or lack thereof) behind each prohibition, and covers what the anti-doping labs are actually testing for. For a technical look at the detection methods themselves, see How Peptide Doping Is Detected: Mass Spectrometry and Biomarker Testing.

The Three-Criteria Framework

WADA does not require proof that a substance enhances performance to ban it. Under Article 4.3.1 of the World Anti-Doping Code, a substance or method can be added to the Prohibited List if it meets any two of three criteria:

1. Performance enhancement: It has the potential to enhance, or does enhance, sport performance.
2. Health risk: It represents an actual or potential health risk to the athlete.
3. Spirit of sport: Its use violates the spirit of sport as described in the Code.

The "spirit of sport" criterion is intentionally broad. WADA defines it as including ethics, fair play, honesty, health, character, and respect for rules. In practice, this means a substance can be banned even if no study has ever shown it improves athletic performance, as long as it poses a health risk and its use is considered contrary to the values of clean sport.

This framework has drawn criticism. A 2019 systematic review by Heuberger and Cohen in Sports Medicine examined the evidence base for all 23 WADA substance classes and found that only 5 had convincing evidence of performance enhancement: anabolic agents, beta-2 agonists, stimulants, glucocorticoids, and beta-blockers. For the remaining 18 classes, including peptide hormones, the authors found no convincing performance data from controlled human studies. The total body of evidence supporting performance enhancement across all prohibited classes was based on only 266 subjects from 11 studies.

This does not mean the bans are arbitrary. WADA's position is that the health risk and spirit of sport criteria carry independent weight. A substance that poses genuine health risks and has no approved medical use can be banned even in the complete absence of performance data. The Prohibited List is reviewed annually by WADA's List Expert Advisory Group, which includes scientists, physicians, and anti-doping specialists who consider new evidence and emerging doping trends. The annual review process means substances can be added, reclassified, or removed as evidence evolves.

Section S2: What Peptides Are Banned and Why

The S2 category of the Prohibited List is titled "Peptide Hormones, Growth Factors, Related Substances and Mimetics." Everything in S2 is banned at all times, meaning athletes cannot use these substances during competition or during training. All S2 substances are classified as "non-Specified," which means that even inadvertent use carries severe penalties, including up to a four-year ban for a first offense.

S2 is divided into three subsections, each targeting a different class of peptides.

S2.1: Erythropoietin and Agents Affecting Erythropoiesis

This subsection covers erythropoietin (EPO) receptor agonists, including recombinant EPO (rHuEPO), darbepoetin, and EPO-mimetic peptides. EPO increases red blood cell production, raising the oxygen-carrying capacity of blood. The rationale for banning EPO is straightforward: more oxygen delivery to muscles during exercise could increase endurance performance.

The evidence, however, is more complicated than the ban suggests. A 2013 review in the British Journal of Clinical Pharmacology found that the scientific literature does not support the conclusion that rHuEPO enhances performance in elite cyclists, and a 2017 double-blind randomized controlled trial showed that while rHuEPO improved maximal exercise capacity in a lab setting, it did not improve road race performance or submaximal exercise. EPO thickens blood and increases clotting risk, which is the health basis for its prohibition. Several cycling deaths in the 1990s were attributed to EPO-related cardiovascular events, though definitive proof was never established. For more on EPO's history in sport, see our dedicated article.

Anti-doping labs now also monitor novel EPO-mimetic agents. Pegmolesatide, a synthetic PEGylated peptide EPO-receptor agonist originally developed for chronic kidney disease anemia, was identified as a potential doping agent and methods for its detection in urine have been developed using liquid chromatography-high resolution mass spectrometry.^[1]

S2.2: Peptide Hormones and Their Releasing Factors

This is the largest subsection and covers multiple peptide families:

Growth hormone (GH), its analogues and fragments. Recombinant human growth hormone (rhGH) is the most recognizable banned peptide. Athletes use GH for its purported effects on lean body mass, recovery, and body composition. But the evidence for actual sport performance enhancement is weak. A systematic review in the Annals of Internal Medicine found that while GH increases lean body mass, it does not clearly improve strength, power, or aerobic capacity in athletes. GH is banned primarily on the potential for performance enhancement combined with health risks (including joint pain, insulin resistance, and potential cancer risk from sustained supraphysiological levels).

Growth hormone fragments like AOD-9604 are also banned. AOD-9604 is the C-terminal fragment of hGH (amino acids 177-191) that was investigated for fat metabolism applications but failed to show efficacy in human clinical trials for obesity. Despite the lack of therapeutic approval, it remains prohibited because it is a GH fragment and falls under the S2.2 definition. For more on AOD-9604's research profile, see our separate article.

Growth hormone releasing peptides (GHRPs). This class includes GHRP-2 (pralmorelin), GHRP-6, hexarelin, and several other synthetic peptides that stimulate pituitary GH release. The rationale for banning GHRPs is indirect: they increase endogenous GH secretion, and GH is prohibited. Even though the evidence that GH itself improves sport performance is limited, anything that raises GH levels is banned by extension.

Seized doping materials have revealed that the gray market continuously produces modified GHRPs to evade detection. A 2019 analysis by Gajda et al. identified glycine-modified growth hormone secretagogues in confiscated doping products, variants not yet on the official prohibited list but covered by WADA's catch-all clauses.^[2]

Growth hormone releasing hormone (GHRH) and its analogues. Substances like sermorelin, tesamorelin, and CJC-1295 stimulate GH release through the GHRH receptor rather than the ghrelin/GHS receptor pathway used by GHRPs. The ban rationale is the same: indirect GH elevation. For more on MK-677 (ibutamoren), an oral GH secretagogue, see our dedicated breakdown.

GnRH and its agonist analogues. Gonadotrophin-releasing hormone (GnRH) agonists like goserelin and leuprolide are banned in males because they can stimulate testosterone production. In females, GnRH agonists are not prohibited. This sex-specific prohibition reflects the different physiological effects: in males, GnRH can increase luteinizing hormone (LH) release, stimulating testicular testosterone synthesis.

Ghrelin and ghrelin mimetics. Ghrelin is the endogenous hunger hormone that also stimulates GH release. Detection of ghrelin manipulation is challenging because the peptide is naturally present in blood and has a short half-life. Thomas et al. developed methods to distinguish between endogenous ghrelin and exogenous ghrelin administration using LC-MS/MS, targeting both acylated ghrelin and desacyl ghrelin in plasma and urine.^[3]

S2.3: Growth Factors and Growth Factor Modulators

This subsection covers:

• IGF-1 (insulin-like growth factor 1) and its analogues
• FGFs (fibroblast growth factors)
• HGF (hepatocyte growth factor)
• MGFs (mechano growth factors)
• PDGF (platelet-derived growth factor)
• VEGF (vascular endothelial growth factor)
• Thymosin beta-4 and its derivatives (e.g., TB-500)

The inclusion of thymosin beta-4 (TB-4) and TB-500 reflects WADA's concern about growth factors that affect "muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching." This is a performance-neutral framing: the ban is not based on evidence that TB-4 makes athletes faster but on the theoretical potential for it to accelerate recovery from injuries, which could give an unfair competitive advantage.

TB-500 detection was first developed for equine doping control. Ho et al. published a validated method for detecting TB-500 (a synthetic version of thymosin beta-4's active region, amino acids 17-23) in horse plasma as early as 2012, well before it appeared on the human anti-doping radar.^[4] The horse racing industry served as an early warning system for human doping: substances used to accelerate equine injury recovery frequently migrate to human athletics within a few years.

More recently, Delcourt et al. established a population study and strategy for detecting thymosin beta-4 misuse in horses, providing reference ranges for distinguishing natural TB-4 levels from exogenous administration.^[5] This population-based approach is critical because TB-4 is naturally present in blood, making it impossible to detect misuse based solely on the presence of the molecule. Instead, labs must determine whether concentrations exceed normal physiological ranges.

The Special Case of BPC-157

BPC-157 occupies an unusual position on the Prohibited List. It was not added under S2 (Peptide Hormones) but under S0 (Non-Approved Substances), a catch-all category that covers "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use."

This classification means BPC-157 is banned not because WADA has determined it enhances performance or poses a specific health risk, but because it has no approved human therapeutic use. The logic is precautionary: unapproved substances carry unknown risks and unknown performance effects, so they are prohibited by default. BPC-157 was added to the Prohibited List in January 2022.

For athletes, the practical consequence is clear: any detectable BPC-157 in a sample is an anti-doping rule violation. For the science, the S0 classification is telling. It signals that WADA does not have evidence that BPC-157 enhances performance. It simply has no evidence that it does not, and the lack of regulatory approval makes it prohibited by default. For BPC-157's regulatory situation with the FDA, see our separate analysis.

How Anti-Doping Labs Detect Peptides

Detecting banned peptides is among the most technically challenging tasks in anti-doping science. Peptides are present at very low concentrations in biological samples, have short half-lives, and in some cases are identical or nearly identical to substances the body produces naturally.^[6]

The primary analytical approach is liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS). This technology can detect peptides at concentrations as low as picograms per milliliter in blood and urine. The process typically involves:

1. Sample preparation: Immunoaffinity purification or solid-phase extraction to isolate peptides from the biological matrix
2. Chromatographic separation: Ultra-high-performance liquid chromatography (UHPLC) to separate peptide species
3. Mass spectrometric detection: High-resolution accurate mass measurement to identify peptides by molecular weight and fragmentation pattern

A comprehensive 2021 review by Judak et al., covering a decade of progress in small peptide doping analysis, documented the expansion from detecting a handful of peptides to comprehensive multi-target screening methods capable of identifying hundreds of compounds in a single analytical run.^[7]

The newer frontier is blood-based testing. Thomas et al. developed methods for probing blood samples for peptidic drugs in the 2-10 kDa range, a molecular weight window that covers most growth factors and hormone-releasing peptides.^[8] Dried blood spot testing, which enables more convenient sample collection and storage, has also been validated for detecting lower molecular mass peptide doping agents.^[9]

One of the central challenges is the constant emergence of new analogs. When anti-doping labs develop a test for GHRP-2, doping suppliers produce GHRP variants with slight structural modifications that evade the test. Gomez-Guerrero et al. described how synthetic reference peptides are now used as analytical standards, enabling labs to detect novel analogs based on predicted fragmentation patterns rather than requiring a reference sample of each new compound.^[10] Thevis et al. reviewed the broader challenge of detecting peptidic drug candidates and analogs that may never have been approved for therapeutic use but are available through gray-market suppliers.^[11]

For more on how testing is evolving, see Emerging Peptide Doping Threats: What Anti-Doping Labs Watch For and The Athlete Biological Passport: How Longitudinal Data Catches Peptide Users. For the broader context of how peptide doping detection works in practice, see our 2026 methods overview.

The Next Frontier: Preemptive Monitoring

Anti-doping science is shifting from reactive detection (waiting for athletes to use a substance, then developing a test) to preemptive monitoring. Researchers now profile the metabolism of emerging weight-loss and performance-adjacent peptides before they appear in doping samples.

Al-Halabi et al. published an in vitro metabolic profiling study of weight-loss-inducing amylin receptor agonists in 2026, specifically to prepare anti-doping methods for compounds that have not yet been used in doping but are likely to be.^[12] This represents a paradigm shift: rather than playing catch-up with the doping market, labs are now characterizing the metabolic signatures of drugs still in pharmaceutical development.

Philip et al. similarly characterized the growth hormone secretagogue ibutamoren (MK-677) and its possible metabolites using liquid chromatography-mass spectrometry, establishing detection windows and analytical methods before widespread abuse was confirmed.^[13] This type of preemptive research is what allows WADA to add substances to the Prohibited List with confidence that they can be detected if athletes use them.

The preemptive approach is particularly important for the GLP-1 receptor agonist class. As weight-loss drugs like semaglutide and tirzepatide gain mainstream popularity, anti-doping authorities anticipate potential misuse for body composition manipulation in weight-class sports. Metabolic profiling of these compounds is already underway in anti-doping research contexts, even though GLP-1 agonists are not currently on the Prohibited List. The S2 category's language about substances affecting "energy utilization" provides a potential future pathway for prohibition if evidence of misuse in sport emerges.

The Evidence Gap Problem

The disconnect between WADA's bans and the evidence of performance enhancement deserves candid examination. For peptide hormones specifically:

Growth hormone: Multiple systematic reviews have failed to show that GH improves strength, power, or endurance in trained individuals. The most consistent finding is an increase in lean body mass, which may reflect water retention rather than functional muscle gain.

GHRPs and GH secretagogues: These are banned because they raise GH, but the evidence that the GH they raise improves sport performance is the same weak evidence described above. The ban is based on the precautionary principle rather than demonstrated efficacy.

EPO: The strongest case for performance enhancement exists here, though even EPO's effects in elite athletes are debated. The health risks (polycythemia, thrombosis, cardiovascular death) are well-established.

TB-500 and BPC-157: No controlled human studies have examined whether these peptides improve athletic performance. They are banned on theoretical grounds (recovery enhancement for TB-500) or as unapproved substances (BPC-157). The animal research on BPC-157 is extensive, with over 500 published papers, but the vast majority are rodent studies from a single research group in Croatia. No human randomized controlled trial has been published. For the broader landscape of peptide use in sports injury rehabilitation, the evidence base remains almost entirely preclinical.

This evidence gap does not mean the bans are unjustified. WADA's framework explicitly allows prohibition based on health risk and spirit of sport, without requiring proof of performance enhancement. The precautionary logic is defensible: if a substance might enhance performance, cannot be monitored for safety, and has no approved medical use, banning it protects athletes from pressure to use unregulated compounds to remain competitive.

But athletes and the public should understand the distinction. "WADA-banned" does not necessarily mean "proven performance-enhancing." The two categories overlap for some substances (anabolic steroids, stimulants) but diverge substantially for others (BPC-157, TB-500, many growth factors). Understanding where a specific peptide falls on this spectrum requires looking at the actual evidence, not just its presence on the Prohibited List.

The Bottom Line

WADA bans peptides under a three-criteria framework requiring only two of: performance enhancement, health risk, or spirit of sport violation. Section S2 covers peptide hormones, growth factors, and their mimetics, all prohibited at all times. The evidence for actual performance enhancement varies widely across banned peptide classes, with the strongest case for EPO and the weakest for growth factors like TB-500 and BPC-157. Anti-doping labs use LC-HRMS to detect peptides at picogram concentrations and are increasingly profiling emerging peptides before they appear in doping samples.

Frequently Asked Questions

What peptides are banned by WADA?

WADA prohibits growth hormone, EPO, GHRPs (GHRP-2, GHRP-6, hexarelin), GH releasing hormones (sermorelin, CJC-1295, tesamorelin), IGF-1, thymosin beta-4 and TB-500, GnRH agonists (in males), ghrelin mimetics, and all growth factors affecting muscle, tendon, or ligament biology. BPC-157 is banned separately under the S0 Unapproved Substances category. The list is reviewed and updated annually.

Why does WADA ban peptides with no evidence of performance enhancement?

WADA's framework does not require proof of performance enhancement. A substance can be prohibited if it meets any two of three criteria: it enhances performance, it poses a health risk, or it violates the spirit of sport. Many peptides are banned on health-risk and spirit-of-sport grounds even when no controlled human study has demonstrated they improve athletic performance.

Is BPC-157 on the WADA banned list?

Yes. BPC-157 was added to the WADA Prohibited List in January 2022 under the S0 (Non-Approved Substances) category. This means it is banned because it has no governmental regulatory approval for human therapeutic use, not because WADA has determined it enhances performance. Any detectable amount in an athlete's sample constitutes an anti-doping rule violation.

How do anti-doping labs detect peptide doping?

Anti-doping laboratories primarily use liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS) to detect banned peptides. This technology can identify peptides at picogram-per-milliliter concentrations in blood and urine. The process involves immunoaffinity purification, chromatographic separation, and mass spectrometric identification based on molecular weight and fragmentation patterns.

Are all growth hormone peptides banned in sport?

Yes. WADA prohibits growth hormone itself, all GH analogues and fragments (including AOD-9604), all growth hormone releasing peptides (GHRP-2, GHRP-6, hexarelin, GHRP-1, GHRP-3, GHRP-4, GHRP-5), growth hormone releasing hormone and its analogues (sermorelin, tesamorelin, CJC-1295), and ghrelin mimetics. These are prohibited at all times, both in- and out-of-competition, with no Specified Substance exceptions.

What happens if an athlete tests positive for a banned peptide?

All S2 substances are classified as "non-Specified," which carries more severe penalties than Specified Substance violations. A first offense involving a non-Specified Substance carries a standard four-year ban from competition unless the athlete can demonstrate the violation was not intentional. The burden of proof falls on the athlete to establish lack of intent.